Literature DB >> 1316541

Half-site spacing and orientation determines whether thyroid hormone and retinoic acid receptors and related factors bind to DNA response elements as monomers, homodimers, or heterodimers.

B M Forman1, J Casanova, B M Raaka, J Ghysdael, H H Samuels.   

Abstract

The receptors for thyroid hormone (T3R) and retinoic acid (RAR) are members of a nuclear receptor subfamily that are capable of recognizing similar DNA sequences. Native response elements for T3R and RAR consist of two or more putative half-site binding motifs organized as imperfect direct or inverted repeats separated by different sized nucleotide gaps. To clarify how T3R, RAR, and related factors recognize DNA response elements, we analyzed the interaction of purified receptors with a series of inverted and direct repeats of an idealized AGGTCA half-site separated by different sized nucleotide gaps. Our results indicate that RAR and T3R can bind to half-sites as monomers and, depending on the orientation and distance between half-sites, also bind as homodimers or T3R-RAR heterodimers. T3R also binds to certain DNA elements as a heterodimer with one or more nuclear factors from eucaryotic cells. Thus, the orientation and spacing of half-sites play a central role in determining which configuration of receptors and nuclear factors will interact with a specific DNA element. This along with the ability of these factors to participate in reversible protein-protein interactions serve to broaden and diversify the responses mediated by T3R, RAR, and related members of this nuclear receptor subfamily.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1316541     DOI: 10.1210/mend.6.3.1316541

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  69 in total

1.  Domain structure of the NRIF3 family of coregulators suggests potential dual roles in transcriptional regulation.

Authors:  D Li; F Wang; H H Samuels
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

2.  SMRT and N-CoR corepressors are regulated by distinct kinase signaling pathways.

Authors:  Brian A Jonas; Martin L Privalsky
Journal:  J Biol Chem       Date:  2004-10-18       Impact factor: 5.157

3.  Heterodimers of retinoic acid receptors and thyroid hormone receptors display unique combinatorial regulatory properties.

Authors:  Sangho Lee; Martin L Privalsky
Journal:  Mol Endocrinol       Date:  2005-01-13

4.  Multiple mutations contribute to repression by the v-Erb A oncoprotein.

Authors:  Sangho Lee; Martin L Privalsky
Journal:  Oncogene       Date:  2005-10-13       Impact factor: 9.867

5.  Multiple parameters determine the specificity of transcriptional response by nuclear receptors HNF-4, ARP-1, PPAR, RAR and RXR through common response elements.

Authors:  H Nakshatri; P Bhat-Nakshatri
Journal:  Nucleic Acids Res       Date:  1998-05-15       Impact factor: 16.971

6.  Novel mechanism of steroid action in skin through glucocorticoid receptor monomers.

Authors:  N Radoja; M Komine; S H Jho; M Blumenberg; M Tomic-Canic
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

7.  Regulation of the mdm2 oncogene by thyroid hormone receptor.

Authors:  J S Qi; Y Yuan; V Desai-Yajnik; H H Samuels
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

8.  DNA bending by thyroid hormone receptor: influence of half-site spacing and RXR.

Authors:  K Shulemovich; D D Dimaculangan; D Katz; M A Lazar
Journal:  Nucleic Acids Res       Date:  1995-03-11       Impact factor: 16.971

9.  The erbA oncogene represses the actions of both retinoid X and retinoid A receptors but does so by distinct mechanisms.

Authors:  H W Chen; M L Privalsky
Journal:  Mol Cell Biol       Date:  1993-10       Impact factor: 4.272

10.  Interaction of human beta 1 thyroid hormone receptor and its mutants with DNA and retinoid X receptor beta. T3 response element-dependent dominant negative potency.

Authors:  C A Meier; C Parkison; A Chen; K Ashizawa; S C Meier-Heusler; P Muchmore; S Y Cheng; B D Weintraub
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.